Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05532813
Other study ID # APHP220832
Secondary ID 2023-507660-39-0
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date March 2024
Est. completion date October 2026

Study information

Verified date January 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Pascal LAFORÊT, MD, PhD
Phone +33 (0)1 47 10 77 36
Email pascal.laforet@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study team hypothesize that non-diabetic patients with Myotonic dystrophy type I (DM1) will improve their symptoms, especially their motor deficit which is the main feature of the disease, because of the splicing defect correction by metformin. The primary objective of the study is to evaluate the efficacy of metformin vs placebo, on the improvement of muscle function in patients with DM1 compared to its placebo. As the secondary objectives, the study aims: - To evaluate the safety of metformin on patient with DM1. - To evaluate the efficacy of metformin vs placebo on: 1. The hand-grip strength; 2. The thumb-index pinch strength; 3. The locomotor function; 4. The respiratory function; 5. The cardiac function; 6. The quality of life; 7. The daily and social activity.


Description:

This is a multicenter, national, comparative study comparing the efficacy and safety of metformin and placebo in patients (1:1 ratio between the 2 groups) with DM1. Population of study participants: patients with biochemically and/or genetically confirmed DM1 disease already followed in the referral and competence departments, as well as new patients. All patients will be included by a neuromuscular specialist from French centers participating in the research. Enrolled patients were randomly assigned (71 patients per group with 1:1 ratio) to either metformin therapy or a placebo, using a centralized randomization procedure. Metformin or placebo will be administered orally and titrated as recommended in diabetic patients. Initial digestive effects (nausea, vomiting and constipation) of metformin that can be observed in the first days. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week. In case of bad digestive tolerance, the dosage should be decrease and the maximum tolerated dosage of metformin should be used. The evaluations of muscle function, walking test, respiratory and cardiac function, quality of life, and tolerance will be assessed at M6 and M12, in the neuromuscular centers. With the estimated effect size, we believe that the inclusion capacities evaluated at 8 to 12 patients per center over one year (18 reference centers involved) will allow to determine a significant difference of MFM score 12 months after inclusion. Dose titration, monitoring of side effects and dose adjustments will be assessed at each visit according to the site endocrinologist advice, if necessary. Statistical analysis: The difference between the score at 12 months and baseline will be compared between treatment groups using the Student T-test. Secondary efficacy endpoints evaluating the evolution of symptoms will be analyzed using either a GMM or a GEE for continuous and categorical variables, respectively. Other quantitative variables will be compared using the Student t-test (or a non-parametric test if the distribution remains skewed following transformation), while categorical variables will be analyzed using either the Chi-squared or the Fisher-exact tests. All efficacy endpoints will be analysed on an intention-to- treat basis and safety endpoints on a per-protocol basis. All statistical tests will be performed with a level of significance of 5%. No interim analysis will be performed.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 142
Est. completion date October 2026
Est. primary completion date October 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - DM1 disease confirmed by genetic analysis - Men and women between 18 and 70 years of age. - Preserved walking abilities (stick assistance possible) - MIRS score 3 or 4 - Women of childbearing potential under efficient contraception during treatment - Patient able to consent - All patients who have completed and signed the specific information and informed consent form - Affiliation to a social security system Exclusion Criteria: - Pregnant or breast-feeding women - Men with an intention to conceive a child during the time of the study - Contraindications to Metformin (hypersensitivity to metformin or to one of the excipients) - Respiratory: - Patient requiring tracheotomy or - Patient requiring non-invasive-ventilation: - more than 12 hours per day; - insufficiently ventilated - Creatinine clearance inferior to 50 ml/min - Cardiac: - Left ventricular ejection fraction below 35% - Conduction system disease on the electrocardiogram with PR interval >200 ms or QRS duration >110 ms without a pacemaker or an implantable defibrillator or cardiac electrophysiological study performed over the past 5 years - Third-degree or Second degree type II atrioventricular block without a pacemaker or an implantable defibrillator - Sustained ventricular tachycardia - Acute disease that may lead to tissue hypoxia

Study Design


Intervention

Drug:
Treatment taken
Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.

Locations

Country Name City State
France Neurology Department, Raymond-Poincaré hospital - APHP Garches

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

References & Publications (2)

Berard C, Payan C, Hodgkinson I, Fermanian J; MFM Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005 Jul;15(7):463-70. doi: 10.1016/j.nmd.2005.03.004. — View Citation

Landfeldt E, Nikolenko N, Jimenez-Moreno C, Cumming S, Monckton DG, Faber CG, Merkies ISJ, Gorman G, Turner C, Lochmuller H. Change over time in ability to perform activities of daily living in myotonic dystrophy type 1. J Neurol. 2020 Nov;267(11):3235-3242. doi: 10.1007/s00415-020-09970-6. Epub 2020 Jun 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change of muscle function By MFM (Motor Function Measure) scale. The MFM-32 is a widely used sensitive and reliable quantitative functional motor scale, validated for use in various neuromuscular disorders (BĂ©rard et al. 2005) and presenting the advantage to measure precisely, not only the muscle strength but motor function which is the main concern for DM1 patients. at baseline and 12 months
Secondary Safety endpoint Any serious adverse event, especially lactic acidosis. through study completion, an average of 30 month
Secondary Change of muscle function between baseline and 6 months By the MFM (Motor Function Measure) scale. at baseline and 6 months
Secondary The hand-grip strength The hand-grip strength defined by the scores obtained using a manual dynamometry standardized (MyoGrip) baseline, 6 and 12 months
Secondary The thumb-index pinch strength The thumb-index pinch strength defined by the scores obtained using a standardized manual dynamometry (MyoPinch) baseline, 6 and 12 months
Secondary The locomotor function The locomotor function defined by the scores obtained using the 6 Minutes Walking Test. baseline, 6 and 12 months
Secondary The respiratory function The respiratory function, using pulmonary function tests, defined by the Supine Vital Capacity (VC). baseline, 6 and 12 months
Secondary The cardiac function The cardiac function, using transthoracic echocardiography, defined by the left ventricular ejection fraction. baseline, 6 and 12 months
Secondary Quality of life assessement The quality of life defined by the scores obtained using the quality of life in genetic neuromuscular disease questionnaire (QoLgNMD). baseline, 6 and 12 months
Secondary The difference between DM1-ActivC at baseline visit, the visit at 6 months and final visit The activity defined by the scores obtained using the DM1 activity and participation scale for clinical use (DM1-ActivC). baseline, 6 and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05052918 - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes N/A
Recruiting NCT05469659 - Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) Phase 2
Completed NCT00767351 - Variation in Serum Levels of Metformin in Patients With Reduced Renal Function
Recruiting NCT06126029 - Effect of Metformin as Add-on Therapy to Ibuprofen on Disease Activity in Knee Osteoarthritis Patients. Phase 2
Enrolling by invitation NCT05900284 - Safety and Feasibility of Metformin for Sepsis Induced AKI Phase 2
Enrolling by invitation NCT06125587 - Chiglitazar/Metformin in Non-obese Women With PCOS Phase 2/Phase 3
Not yet recruiting NCT05013112 - Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) N/A
Recruiting NCT03525028 - A Clinical Trial of Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis N/A
Recruiting NCT05680805 - Metabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS Phase 4
Recruiting NCT06325956 - PCOS Immune Function Predicts Metformin Efficacy N/A
Recruiting NCT06325969 - PCOS Patients Immune Status Evaluation
Completed NCT03335423 - Inter- and Intra-individual Variations in Metformin Pharmacokinetics - The Importance of Genes and Drug Interactions Phase 1
Recruiting NCT04477590 - Interactions of Medicine and Exercise With Meal Timing N/A
Not yet recruiting NCT06459310 - Pilot Study on Evaluating the Geroprotective Effect of Metformin Phase 2
Not yet recruiting NCT05412056 - Metformin to Prevent Preterm Birth in Twin Pregnancy Phase 2/Phase 3
Terminated NCT01756105 - Efficacy of Metformin in Achieving Glycaemia Goals as Recommended for the Treatment of Gestational Diabetes in Non Obese Women Phase 2
Completed NCT04377451 - Metformin in Dengue With Obesity Phase 1/Phase 2
Completed NCT03618472 - Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells N/A
Recruiting NCT04581447 - Extending Time Without Diabetes After Bariatric Surgery: a Trial Comparing the Metformin Addition or Not to Standard Care Phase 3
Not yet recruiting NCT05655728 - Treatment With Metformin in Chinese Children With Alport Syndrome Phase 4